Olympism365 Summit: building a safer world in and through sport
28 May 2025 - Safe sport will sit high on the agenda…
KEYTRUDA (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
KEYNOTE-689 marks the first positive trial in more than two decades for…
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
April 03, 2025 18:18 ET | Source: Annexon Biosciences Oral Plenary Presentation…
Guangdong Demonstrates Openness, Confidence and Responsibility as an Economic Powerhouse
GUANGZHOU, China, March 7, 2025 /PRNewswire/ -- On the afternoon of March…
